@article {PARK2647, author = {SOO JIN PARK and WHASUN LIM and JAEHEE MUN and HAERIN PAIK and SUNWOO PARK and HYUNJI LIM and JUNHWAN KIM and EUN JI LEE and GA WON YIM and NARA LEE and CHEOL LEE and JAE-WEON KIM and GWONHWA SONG and HEE SEUNG KIM}, title = {SERPINB11 Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary}, volume = {35}, number = {5}, pages = {2647--2653}, year = {2021}, doi = {10.21873/invivo.12547}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: To evaluate the role of serine protease inhibitor B11 (SERPINB11) expression as a prognostic biomarker in high-grade serous carcinoma (HGSC) and clear cell carcinoma of the ovary (CCC). Materials and Methods: We obtained tumor tissues from patients with HGSC (n=145) and CCC (n=59). We evaluated immunohistochemically the expression of SERPINB11 and investigated whether SERPINB11 expression affects platinum-resistance and the prognosis of HGSC and CCC. Results: High expression of SERPINB11 was more common in CCC than in HGSC (57.6\% vs. 28.3\%; p\<0.01), and SEPRINB11 expression did not correlate with platinum-resistance of HGSC and CCC. High expression of SERPINB11 was associated with worse progression-free survival and overall survival with marginal significance in HGSC; no relation between SERPINB11 expression and the prognosis of CCC was found. Conclusion: SERPINB11 expression maybe a prognostic biomarker for HGSC.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/35/5/2647}, eprint = {https://iv.iiarjournals.org/content/35/5/2647.full.pdf}, journal = {In Vivo} }